IMA203 showed an excellent safety profile and promising efficacy in solid tumors, leading to a new registration-directed clinical trial.
Jason Luke, MD, FACP
Advertisement
Jason Luke, MD, FACP, is the associate director for clinical research of Hillman Cancer Center at the University of Pittsburgh.
Articles by Jason Luke, MD, FACP
Jason Luke, MD, FACP, discusses the mechanism of action of IMA203, a novel agent for the treatment of metastatic melanoma.
Jason Luke, MD, FACP, discusses promising clinical research around intratumoral immunotherapy.
Jason J. Luke, MD, FACP, assistant professor of medicine, The University of Chicago, discusses the international MSLT-II trial, which looks at the possibility of less surgery for melanoma patients in the future.
Advertisement
Latest Updated Articles
Promising Results for IMA203 in Melanoma: A PRAME-Targeted TrialPublished: August 19th 2025 | Updated:
Exploring Intratumoral Immunotherapy in Melanoma and Other MalignanciesPublished: February 8th 2020 | Updated:
Dr. Jason Luke on Advances in How Melanoma is DiagnosedPublished: November 3rd 2015 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
